|Articles|October 8, 2021
- Pharmaceutical Executive-10-01-2021
- Volume 41
- Issue 10
Pharmaceutical Executive, October 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
Addressing Systemic Racism in Biopharmaover 4 years ago
Understanding the HCP: Patient-Level Data Proves Valuableover 4 years ago
Industry Game Changer: RWE Impacts on Drug Developmentover 4 years ago
Opposites Attractover 4 years ago
Defining the Chief Data Officerover 4 years ago
Leading Through Transitionover 4 years ago
Biotech Stocks Continue With Underperformanceover 4 years ago
Could Time Be the Next New Element in Pharma Revenue?over 4 years ago
Sharing the Science: Pharma’s Content Evolutionover 4 years ago
Data Science Calls for Shift in Executive Leadership MethodsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Regeneron Enters $2.1 Billion Radiopharma Collaboration with Telix Pharmaceuticals
2
Travere Therapeutics’ Filspari Receives Full FDA Approval
3
Managing Patient Experience and RWE in Clinical Trials: Q&A with Matt Holms, MB
4
FDA Issues CRL to Replimune for RP1 Biologics License Application for Advanced Melanoma Treatment
5

